Grover P. Miller

Federal Grant PI High Impact

Professor

UAMS primary Harding University Hendrix College University of Central Arkansas

Also affiliated: Chonnam National University (2018); Merck & Co., Inc., Rahway, NJ, USA (United States) (2002); Southwest Research Institute (1991–2016); Pennsylvania State University (1993–2001); University of Helsinki (2009); University of Arizona (2020); Vanderbilt University (2000–2002); Washington University in St. Louis (2009–2020); University of Arkansas Medical Center (2007); Conway School of Landscape Design (2020); Arkansas Department of Health (2009–2010); Westinghouse Electric (United States) (2024)

Faculty Researcher

Biochemistry & Molecular Biology, College of Medicine

30 h-index 110 pubs 2,789 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Grover P. Miller's research program focuses on understanding the biological significance of metabolic activation and clearance of molecules, particularly in relation to pharmacological and toxicological effects. His group employs analytical and biochemical tools to identify and quantify small molecules, such as drugs, pollutants, and food additives, during metabolic processes. These findings are then correlated with biological activity and in vivo outcomes, including liver toxicity.

Key areas of investigation include determining the metabolic mechanisms, efficiencies, and fluxes involved in the activation and elimination of toxic molecules. The research also aims to identify metabolite biomarkers in human and animal models to link in vitro findings with in vivo results, exploring their diagnostic, theragnostic, and prognostic potential. Furthermore, the group develops computational models to predict drug bioactivation and clearance, contributing to the reduction of adverse drug events and the enhancement of drug safety in clinical use. Miller also seeks to translate novel analytical and diagnostic tools into practical, commercially viable applications.

His work has resulted in over 100 publications and significant citations, with an h-index of 30. Miller has received federal funding for his research, including a $76,500 grant from the NIH/National Institute on Drug Abuse for investigating novel metabolic pathways for halogenated drugs of abuse. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Gunnar Boysen, Samantha Crosby, Sasin Payakachat, and Benjamin Mark Schleiff.

Research Overview

My goals are to assess the biological significance of metabolic activation and clearance of molecules especially related to pharmacological and toxicological effects. In practice, my group leverages powerful analytical and biochemical tools to identify and quantitate small molecules including drugs, pollutants, and food additives during metabolism and correlate findings to biological activity and in vivo outcomes such as liver toxicity. Individual projects aim to (1) determine metabolic mechanisms, efficiencies, and fluxes for activation and elimination of toxic molecules, (2) identify metabolite biomarkers in humans and animal models for correlating in vitro findings to in vivo outcomes and leveraging their diagnostic, theragnostic, and prognostic potential, and (3) develop computational models for drug bioactivation and clearance contributing to adverse drug events to make drugs safer for clinical use. Moreover, I seek translation of novel analytical and diagnostic tools into practical, commercially viable tools. Over time, my research expanded from detailed in vitro metabolic studies to metabolite profiling for translational studies and development of models of metabolism, structure, and reactivity that were made possible through strong, interdisciplinary collaborations.

Metrics

h-index: 30
Publications: 110
Citations: 2,789

Selected Publications

Assessing Pain Linked to High Metabolic and Glycolytic Shift in Neurofibromatosis Type 1 (NF1) Patients by Using a Bioenergetic Biomarker: A Pilot Study (2026)

Cureus DOI OpenAlex
The resurgence of synthetic cannabinoid receptor agonists as adulterants in the Era of Cannabis legalization: Lessons from prior epidemics and clinical implications (2025)

Neuroscience & Biobehavioral Reviews 8 citations DOI OpenAlex
Bioactivation and reactivity research advances – 2023 year in review (2024)

Drug Metabolism Reviews 1 citation DOI OpenAlex
Biotransformation research advances – 2022 year in review (2023)

Drug Metabolism Reviews 5 citations DOI OpenAlex
Bioactivation and reactivity research advances – 2022 year in review‡ (2023)

Drug Metabolism Reviews DOI OpenAlex
The Role of Cytochrome P450 3A4-Mediated Metabolism in Sorafenib and Lapatinib Hepatotoxicity (2023)

Livers 12 citations DOI OpenAlex
Editorial: Advancements in computational studies of drug toxicity (2023)

Frontiers in Pharmacology 5 citations DOI OpenAlex
Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes (2022)

Metabolites 2 citations DOI OpenAlex
Bioactivation and reactivity research advances – 2021 year in review (2022)

Drug Metabolism Reviews 3 citations DOI OpenAlex
Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin (2022)

Frontiers in Pharmacology 1 citation DOI OpenAlex
CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs (2021)

Biochemical Pharmacology 7 citations DOI OpenAlex
Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort (2021)

PLoS Computational Biology 45 citations DOI OpenAlex
4-Methyl-1,2,3-Triazoles as <i>N</i>-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity (2021)

Journal of Medicinal Chemistry 36 citations DOI OpenAlex
Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors (2021)

Metabolites 3 citations DOI OpenAlex
Novel Bioactivation of Isoxazole‐containing Bromodomain and Extra Terminal Domain (BET) Inhibitors (2021)

The FASEB Journal DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 2 $84,000 total

NIH Contact PI Aug 2026 - Jul 2027

Advances in toxicological mechanisms through interdisciplinary research

National Institute of Environmental Health Sciences $7,500 R13

NIH Contact PI Sep 2025 - Aug 2027

Novel metabolic pathway for halogenated drugs of abuse

National Institute on Drug Abuse $76,500 R03

Research Interests

drug; metabolism; bioactivation; toxicity; in vitro; P450; modeling; Structure Activity Relationship, Quantitative; kinetics

Grants & Funding

As listed on this researcher's institutional profile. Federal awards with verified records are shown above.

RATE LIMITING STEPS IN CYTOCHROME P450 CATALYSIS NIH Principal Investigator
Structure-Function of UDP-Glucuronosyltransferases NIH Co-Investigator
Investigating the Role of Protein-protein Interactions in the Oxidation of Fatty Acids by Cytochrome P4504A11 American Heart Association (Midwest Affiliate) Principal Investigator
Improving pediatric anticoagulant therapy through metabolic profiling of patients American Heart Association (SouthWest Affiliate) Principal Investigator
NIH COBRE Center for Protein Structure and Function NIH/Nat. Center for Research Resources Principal Investigator
Effects of Genetic Diversity on Carcinogen Metabolism NIH Co-Investigator
Miller ABI Contract UAMS College of Medicine Principal Investigator
Toxicological Significance of Alkylbenzene Metabolism NIH/Nat. Inst. of Environmental Health Sciences via Louisiana State University Health Sciences Center Principal Investigator